domain protein-1/hypoxia-inducible factor-2α (EPAS-1/ HIF-2α) is a catabolic transcription factor that regulates osteoarthritis (OA) cartilage destruction. Objectives: In this study, we examined whether microRNA-365 (miR-365) affects interleukin (IL)-1β-induced expression of catabolic factors in chondrocytes via regulation of HIF-2α. Methods: Total RNA was isolated from normal and OA cartilage tissues and human chondrocytes. miR-365 expression was quantified by TaqMan assay. The effects of miR-365 on HIF-2α and HIF-2α-modulated genes were assessed by quantitative real-time reverse polymerase chain reaction (qRT-PCR), Western blot analysis, and enzyme-linked immunosorbent assay (ELISA). Direct interaction of miR-365 with the 3' untranslated region (UTR) of HIF-2α mRNA was examined using a luciferase reporter assay. Nitrite concentration was measured in culture medium using a Griess assay. Results: miR-365 levels were significantly decreased in human OA cartilage relative to normal cartilage. Overexpression of miR-365 significantly suppressed IL-1β-induced expression of HIF-2α in human articular chondrocytes. Pharmacological inhibition of various IL-1β-associated signaling pathways revealed mitogen-activated protein kinase and nuclear factor-κB as the primary pathways driving IL-1β-mediated decreases in miR-365 and subsequent increase in HIF-2α expression. Using a luciferase reporter assay encoding the 3'UTR of human HIF-2α mRNA, we showed that overexpression of miR-365 significantly suppressed IL-1β-induced up-regulation of HIF-2α. Furthermore, miR-365 overexpression significantly suppressed IL-1β-induced expression of catabolic factors, including cyclooxygenase-2, inducible nitric oxide synthase, and matrix metalloproteinase-1, -3 and -13, and nitric oxide (NO) production in chondrocytes. 
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Conclusions
Results: Baseline circulating TNF bioactivity was similar according to Eular response. However, circulating TNF bioactivity at 6 month was associated with clinical response with low TNF bioactivity in responders. A ROC analysis suggested a cut-off at 0.320 with a sensitivity at 92% and a specificity at 41%. Conclusions: After a failure of a first TNF blocker, circulating TNF bioactivity is not able to predict response to a second TNF blocker despite a lower level in responders compared to non-responders. 
